Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
Journal
Liver cancer
Journal Volume
12
Journal Issue
5
Date Issued
2023-10
Author(s)
Kudo, Masatoshi
Finn, Richard S
Zhu, Andrew X
Ducreux, Michel
Galle, Peter R
Sakamoto, Naoya
Kato, Naoya
Nakano, Michitaka
Jia, Jing
Vogel, Arndt
Abstract
Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of a baseline albumin-bilirubin (ALBI) score.
Subjects
Albumin-bilirubin grade; Atezolizumab; Bevacizumab; Unresectable hepatocellular carcinoma
SDGs
Type
journal article